A Phase 2a Multi-Centre, Double Blind, Placebo Controlled Cross-Over Trial To Investigate The Efficacy, Safety And Toleration Of CP-866,087 In Pre-Menopausal Women Diagnosed With Female Sexual Arousal Disorder (FSAD).
Phase of Trial: Phase II
Latest Information Update: 01 Oct 2013
At a glance
- Drugs CP 866087 (Primary)
- Indications Female sexual dysfunction
- Focus Therapeutic Use
- Sponsors Pfizer
- 03 Nov 2008 Actual end date changed from 1 Nov 2008 to 1 Oct 2008 as reported by Clinicaltrials.gov.
- 03 Nov 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 02 Apr 2008 New locations added according to ClinicalTrials.gov.